96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04186247 (ClinicalTrials.gov) | December 2021 | 2/12/2019 | Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD) | Personalized AZithromycin/metronidAZole, in Combination With Standard Induction Therapy, to Achieve a Fecal Microbiome Community Structure and Metagenome Changes Associated With Sustained Remission in Pediatric Crohn's Disease (CD): a Pilot Study | Crohn Disease;Pediatric Crohns Disease | Drug: Azithromycin;Drug: Metronidazole;Other: Standard of Care | University of North Carolina, Chapel Hill | Crohn's and Colitis Foundation;University of Amsterdam | Not yet recruiting | 3 Years | 17 Years | All | 20 | Phase 2 | United States;Canada;Israel;Netherlands |
2 | NCT04682522 (ClinicalTrials.gov) | March 21, 2021 | 9/12/2020 | Flagyl Microbiome in Crohn's Disease | Does the Microbiome Change With Flagyl Treatment After Ileocolic Resection for Crohn's Disease | Crohn Disease | Drug: Metronidazole Oral | University of Louisville | NULL | Recruiting | 20 Years | 80 Years | All | 36 | Phase 4 | United States |
3 | EUCTR2019-004219-29-NL (EUCTR) | 21/04/2020 | 04/02/2020 | Personalized antibiotic therapy in combination with standard therapy to achieve a fecal profile associated with prolonged complaint-free period in pediatric Crohn’s Disease | Personalized AZithromycin/metronidAZole, in combination with standard induction therapy, to achieve a fecal microbiome community structure and metagenome changes associated with sustained remission in pediatric Crohn’s Disease (CD): a pilot study” - PAZAZ | Crohn's Disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Azithromycin Product Name: Azithromycin INN or Proposed INN: Azithromycin Other descriptive name: AZITHROMYCIN Trade Name: Metronidazole Product Name: Metronidazole INN or Proposed INN: METRONIDAZOLE Other descriptive name: METRONIDAZOLE | Amsterdam UMC | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | United States;Canada;Israel;Netherlands | ||
4 | JPRN-UMIN000025846 | 2017/02/01 | 01/02/2017 | A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease | ulcerative colitis, Crohn's disease | Administration of the fecal material from healthy donors to patients after taking three kinds of antibiotics (Amoxicillin, fosmycin, metronidazole) for two weeks | Juntendo university school of medicineDepartment of gastroenterology | NULL | Recruiting | 16years-old | Not applicable | Male and Female | 60 | Not selected | Japan | |
5 | JPRN-jRCTs031180415 | 01/02/2017 | 22/03/2019 | A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease | Single center non-randomized study: A trial of a combination therapy of fecal microbial transplantation and antibiotics for inflammatory bowel disease | Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) | AFM therapy arm : three antibiotics, amoxicillin (1500 mg/day), fosfomycin (3000 mg/day) and metronidazole (750 mg/day) are administered orally to patients for 2 weeks. For pediatric patients, amoxicillin (50mg/kg), fosfomycin (120mg/kg) and metronidazole (20mg/kg) are administered orally for 2 weeks (the upper limit is the same amount as adults). FMT arm : Approximately 150 to 250 g of donor stool is diluted with saline (500 mL) and filtered to remove crude components. The diluted and filtered fecal suspension is transferred into the patients colon from cecum to rectum during total colonoscopy. As usual examinations, the patient undergoes biopsy of inflammatory site. A-FMT arm : Patient undergoes FMT two days after AFM therapy. | Ishikawa Dai | NULL | Recruiting | >= 6age old | Not applicable | Both | 120 | N/A | Japan |
6 | JPRN-UMIN000013369 | 2014/04/01 | 20/03/2014 | Efficacy of preoperative oral antibiotics prophylaxis for prevention of surgical site infections in patients with Crohn's disease | Crohn's disease | Oral antibiotics will be administrated on the day before surgery (500mg of kanamycin and 500mg of metronidazole at 14:00, 15:00, and 21:00) without oral antibiotics | Hyogo college of medicine | NULL | Complete: follow-up complete | 20years-old | 70years-old | Male and Female | 240 | Phase 2 | Japan | |
7 | EUCTR2012-005226-29-PL (EUCTR) | 16/01/2014 | 19/09/2013 | Antibiotic therapy for children with active Crohn's disease | Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease - AZCRO | Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: azithromycin Trade Name: metronidazole Product Name: metronidazole Product Name: azithromycin Product Name: azithromycin | Erasmus MC | Hospital S. Joao;University hospital Brussel;Jagiellonian University Medical College | Not Recruiting | Female: yes Male: yes | 70 | Portugal;United States;Canada;Belgium;Poland;Israel;Netherlands | |||
8 | EUCTR2012-005226-29-PT (EUCTR) | 20/12/2013 | 24/09/2013 | Antibiotic therapy for children with active Crohn's disease | Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease - AZCRO | Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: azithromycin INN or Proposed INN: azithromycin Other descriptive name: AZITHROMYCIN Trade Name: metronidazole Product Name: metronidazole INN or Proposed INN: METRONIDAZOLE Other descriptive name: Metronidazole | Centro Hospitalar de São João E.P.E. | NULL | Not Recruiting | Female: yes Male: yes | 70 | Phase 3 | United States;Portugal;Canada;Poland;Belgium;Israel;Netherlands | ||
9 | EUCTR2012-005226-29-BE (EUCTR) | 26/04/2013 | 14/03/2013 | Antibiotic therapy for children with active Crohn's disease | Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease - AZCRO | Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: azithromycin Trade Name: metronidazole Product Name: metronidazole | Wolfson Medical Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | Portugal;United States;Canada;Poland;Belgium;Israel;Netherlands | |||
10 | NCT01596894 (ClinicalTrials.gov) | October 2012 | 12/4/2012 | Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease | A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's Disease, Using 2 Months Antibiotic Course of Azithromycin Combined With Metronidazole vs. Metronidazole Alone. | Crohn's Disease | Drug: Azithromycin + Metronidazole;Drug: Metronidazole | Prof. Arie Levine | NULL | Completed | 5 Years | 17 Years | All | 73 | Phase 4 | Israel |
11 | NCT01564823 (ClinicalTrials.gov) | June 2012 | 31/1/2012 | Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease | Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease | Crohn´s Disease | Drug: Metronidazole;Drug: Azathioprine;Drug: Adalimumab | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Effice Servicios Para la Investigacion S.L. | Completed | 18 Years | N/A | Both | 86 | Phase 3 | Spain |
12 | EUCTR2011-000885-36-ES (EUCTR) | 26/12/2011 | 29/11/2011 | Adalimub treatment to prevent recurrency post-surgery in Crohn disease. | Multicentric, randomized double blind clinical trial and paralell groups to compare Adalimub vs Azatioprina efficacy prevention in Crhon disease post-surgical recurrency after 52 weeks of treatment - APPRECIA | Compare efficay of Adalimub vs Azatioprina to prevent surgical intervention in Chron disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Humira Product Name: Humira INN or Proposed INN: Adalimumab Other descriptive name: Adalimumab Trade Name: Imurel Product Name: Imurel INN or Proposed INN: Azatioprina Other descriptive name: Imurel Trade Name: Flagyl Product Name: Flagyl INN or Proposed INN: Metronidazol Other descriptive name: Flagyl | GETECCU | NULL | Not Recruiting | Female: yes Male: yes | Spain | ||||
13 | NCT00774969 (ClinicalTrials.gov) | October 2007 | 16/10/2008 | Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease | Phase 1 Study to Evaluate the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri-Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease | Perianal Crohns' | Drug: Metronidazole | S.L.A. Pharma AG | NULL | Completed | 18 Years | 65 Years | Both | 19 | Phase 1 | United Kingdom |
14 | NCT00257699 (ClinicalTrials.gov) | May 2006 | 22/11/2005 | Study of Antibiotics in the Treatment of Colonic Crohn's Disease | Metronidazole and Ciprofloxacin in the Treatment of Colonic Crohn's Disease: The MACINTOCC Trial. | Crohn's Disease | Drug: Metronidazole placebo;Drug: ciprofloxacin placebo;Drug: ciprofloxacin;Drug: metronidazole | Mount Sinai Hospital, Canada | Crohn's and Colitis Foundation | Terminated | 16 Years | N/A | Both | 12 | Phase 2 | Canada |
15 | NCT00509639 (ClinicalTrials.gov) | May 2005 | 30/7/2007 | Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease | Phase III Study to Evaluate the Effect of 10% Metronidazole Ointment, Applied Topically Three Times a Day in and Around the Anus and the Change in Perianal Crohn's Disease Activity | Crohn's Disease | Drug: 10% Metronidazole Ointment | S.L.A. Pharma AG | NULL | Completed | 18 Years | N/A | Both | 74 | Phase 3 | United States;United Kingdom |
16 | EUCTR2012-005226-29-NL (EUCTR) | 08/03/2013 | Antibiotic therapy for children with active Crohn's disease | Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease - AZCRO | Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: azithromycin Trade Name: metronidazole Product Name: metronidazole | Wolfson Medical Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | United States;Canada;Israel;Netherlands |